Cargando…

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma

The BRAF gene and the TERT promoter are among the most frequently altered genomic loci in low-grade (LGG) and high-grade-glioma (HGG), respectively. The coexistence of BRAF and TERT promoter aberrations characterizes a subset of aggressive glioma. Therefore, we investigated interactions between thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gabler, Lisa, Lötsch, Daniela, Kirchhofer, Dominik, van Schoonhoven, Sushilla, Schmidt, Hannah M., Mayr, Lisa, Pirker, Christine, Neumayer, Katharina, Dinhof, Carina, Kastler, Lucia, Azizi, Amedeo A., Dorfer, Christian, Czech, Thomas, Haberler, Christine, Peyrl, Andreas, Kumar, Rajiv, Slavc, Irene, Spiegl-Kreinecker, Sabine, Gojo, Johannes, Berger, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685154/ https://www.ncbi.nlm.nih.gov/pubmed/31391125 http://dx.doi.org/10.1186/s40478-019-0775-6

Ejemplares similares

p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction
por: Dinhof, Carina, et al.
Publicado: (2020)

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients
por: Madlener, Sibylle, et al.
Publicado: (2023)

ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS
por: Madlener, Sibylle, et al.
Publicado: (2023)

ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR)
por: Mayr, Lisa, et al.
Publicado: (2020)

Mechanisms of TERT Reactivation and Its Interaction with BRAF(V600E)
por: Song, Young Shin, et al.
Publicado: (2020)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets
por: Kirchhofer, Dominik, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes
por: Mayr, Lisa, et al.
Publicado: (2020)

CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model
por: Mayr, Lisa, et al.
Publicado: (2017)

EPEN-23. Interaction of epigenetic regulation and telomerase re-activation in high-risk ependymoma
por: Jaunecker, Carola N, et al.
Publicado: (2022)

Targeting fibroblast growth factor receptors to combat aggressive ependymoma
por: Lötsch, Daniela, et al.
Publicado: (2021)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
por: Estrada-Flórez, Ana P, et al.
Publicado: (2019)

ETMR-11. Transcriptional changes upon knockdown of alteredBCOR/BCORL1 transcripts in preclinical models of CNS embryonal tumors with BCOR-related alterations
por: Piontek, Martin, et al.
Publicado: (2022)

EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
por: Sevelda, Florian, et al.
Publicado: (2015)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness
por: Gabler, Lisa, et al.
Publicado: (2022)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD
por: Stepien, Natalia, et al.
Publicado: (2021)

SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?
por: Ciobanu-Caraus, Olga, et al.
Publicado: (2022)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION
por: Mayr, Lisa, et al.
Publicado: (2023)

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
por: Liu, Rengyun, et al.
Publicado: (2018)

Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
por: Wu, Yongxing, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas
por: Dorfer, Christian, et al.
Publicado: (2020)

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China
por: Huang, Meiling, et al.
Publicado: (2019)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

Preoperative detection of TERT promoter and BRAF(V600E) mutations in papillary thyroid carcinoma in high-risk thyroid nodules
por: Giorgenon, Tatiana Marina Vieira, et al.
Publicado: (2019)

Novel Insights into Diagnosis, Biology, and Treatment of Primary Diffuse Leptomeningeal Melanomatosis
por: Baumgartner, Alicia, et al.
Publicado: (2021)

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
por: Jin, Langping, et al.
Publicado: (2016)

Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules
por: Rosvall, Brandon R., et al.
Publicado: (2021)

TERT accelerates BRAF mutant–induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis
por: Yu, Pengcheng, et al.
Publicado: (2023)

BRAF, TERT and HLA-G Status in the Papillary Thyroid Carcinoma: A Clinicopathological Association Study
por: Bertol, Bruna C., et al.
Publicado: (2023)

Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules
por: Fu, Guodong, et al.
Publicado: (2023)

HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020)

Placement of EVD in pediatric posterior fossa tumors: safe and efficient or old-fashioned? The Vienna experience
por: Hedrich, Cora, et al.
Publicado: (2023)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vhksmgllcmaaaa4b41qp7dqfpu